- Home
- AGEN vs WLGS Comparison
AGEN vs WLGS Comparison
Compare AGEN & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- WLGS
- Stock Information
- Founded
- AGEN 1994
- WLGS 1981
- Country
- AGEN United States
- WLGS Hong Kong
- Employees
- AGEN N/A
- WLGS N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- WLGS Engineering & Construction
- Sector
- AGEN Health Care
- WLGS Consumer Discretionary
- Exchange
- AGEN Nasdaq
- WLGS Nasdaq
- Market Cap
- AGEN 38.1M
- WLGS 98.9M
- IPO Year
- AGEN 2000
- WLGS 2023
- Fundamental
- Price
- AGEN $1.61
- WLGS $0.26
- Analyst Decision
- AGEN Buy
- WLGS
- Analyst Count
- AGEN 4
- WLGS 0
- Target Price
- AGEN $8.00
- WLGS N/A
- AVG Volume (30 Days)
- AGEN 500.1K
- WLGS 4.7M
- Earning Date
- AGEN 05-06-2025
- WLGS 04-08-2025
- Dividend Yield
- AGEN N/A
- WLGS N/A
- EPS Growth
- AGEN N/A
- WLGS N/A
- EPS
- AGEN N/A
- WLGS 0.02
- Revenue
- AGEN $103,463,000.00
- WLGS $7,272,879.00
- Revenue This Year
- AGEN $4.03
- WLGS N/A
- Revenue Next Year
- AGEN $5.57
- WLGS N/A
- P/E Ratio
- AGEN N/A
- WLGS $15.36
- Revenue Growth
- AGEN N/A
- WLGS 66.93
- 52 Week Low
- AGEN $1.44
- WLGS $0.23
- 52 Week High
- AGEN $19.69
- WLGS $9.66
- Technical
- Relative Strength Index (RSI)
- AGEN 21.45
- WLGS 27.43
- Support Level
- AGEN $1.44
- WLGS $0.23
- Resistance Level
- AGEN $1.77
- WLGS $5.85
- Average True Range (ATR)
- AGEN 0.13
- WLGS 0.43
- MACD
- AGEN 0.02
- WLGS -0.36
- Stochastic Oscillator
- AGEN 8.00
- WLGS 0.36
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.